Patents by Inventor Andreas Bruederle

Andreas Bruederle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9642918
    Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: May 9, 2017
    Assignees: Pfizer Inc., Oncology Institute of Southern Switzerland
    Inventors: Andreas Bruederle, Padraig Moran, Anastasios Stathis
  • Publication number: 20140335109
    Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 13, 2014
    Applicant: ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
    Inventors: Andreas Bruederle, Padraig Moran, Anastasios Stathis